In silico identification of novel stilbenes analogs for potential multi-targeted drugs against Alzheimer’s disease

被引:0
|
作者
Sundas Firdoos
Rongji Dai
Rana Adnan Tahir
Zahid Younas Khan
Hui Li
Jun Zhang
Junjun Ni
Zhenzhen Quan
Hong Qing
机构
[1] Beijing Institute of Technology,Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science
[2] Beijing Institute of Technology (BIT),Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceutical
[3] COMSATS University Islamabad,Department of Biosciences
[4] Sahiwal Campus,Department of Computer Science and IT
[5] University of Azad Jammu and Kashmir,undefined
来源
关键词
Stilbenes; Neurodegenerative disorders; Alzheimer’s disease; Bioinformatics; Molecular docking; Molecular dynamic simulations; Neurotrophins;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [31] Synthesis and evaluation of quinoline analogs as potential drugs in Alzheimer's disease
    Malik, Seema
    Sangwan, Abhijeet
    Piplani, Poonam
    Marco Coutelles, Jose
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [32] In silico Docking Studies and Potential Lead Identification against JNK3 for Alzheimer's Disease
    Singh, Nishtha
    Upadhyay, Sonal
    Jaiswar, Ankur
    Mishra, Nidhi
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2019, 9 (04) : 220 - 222
  • [33] Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer's Disease Through Activation of Canonical Wnt/β-Catenin Signalling Pathway
    Machhi, Jatin
    Sinha, Anshuman
    Patel, Pratik
    Kanhed, Ashish M.
    Upadhyay, Pragnesh
    Tripathi, Ashutosh
    Parikh, Zalak S.
    Chruvattil, Ragitha
    Pillai, Prakash P.
    Gupta, Sarita
    Patel, Kirti
    Giridhar, Rajani
    Yadav, Mange Ram
    NEUROTOXICITY RESEARCH, 2016, 29 (04) : 495 - 513
  • [34] Neuroprotective Potential of Novel Multi-Targeted Isoalloxazine Derivatives in Rodent Models of Alzheimer’s Disease Through Activation of Canonical Wnt/β-Catenin Signalling Pathway
    Jatin Machhi
    Anshuman Sinha
    Pratik Patel
    Ashish M. Kanhed
    Pragnesh Upadhyay
    Ashutosh Tripathi
    Zalak S. Parikh
    Ragitha Chruvattil
    Prakash P. Pillai
    Sarita Gupta
    Kirti Patel
    Rajani Giridhar
    Mange Ram Yadav
    Neurotoxicity Research, 2016, 29 : 495 - 513
  • [35] Semisynthesis and biological evaluation of prenylated resveratrol derivatives as multi-targeted agents for Alzheimer’s disease
    Thanchanok Puksasook
    Shinya Kimura
    Sarin Tadtong
    Jutamas Jiaranaikulwanitch
    Jaturong Pratuangdejkul
    Worawan Kitphati
    Khanit Suwanborirux
    Naoki Saito
    Veena Nukoolkarn
    Journal of Natural Medicines, 2017, 71 : 665 - 682
  • [36] Survey of New, Small-Molecule Isatin-Based Oxindole Hybrids as Multi-Targeted Drugs for the Treatment of Alzheimer's Disease
    Marques, Carolina S.
    Lopez, Oscar
    Leitzbach, Luisa
    Fernandez-Bolanos, Jose G.
    Stark, Holger
    Burke, Anthony J.
    SYNTHESIS-STUTTGART, 2022, 54 (19): : 4304 - 4319
  • [37] Novel Tacrine Analogs as Potential Cholinesterase Inhibitors in Alzheimer's Disease
    El-Malah, Afaf
    Gedawy, Ehab M.
    Kassab, Asmaa E.
    Salam, Rania M. Abdel
    ARCHIV DER PHARMAZIE, 2014, 347 (02) : 96 - 103
  • [38] In silico designed microtubule-stabilizer drugs against tauopathy in Alzheimer's disease
    Sarukhanyan, Edita
    Dandekar, Thomas
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (18): : 8992 - 9012
  • [39] Drugs for Targeted Therapies of Alzheimer's Disease
    Tam, Chit
    Wong, Jack Ho
    Ng, Tzi Bun
    Tsui, Stephen Kwok Wing
    Zuo, Tao
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (02) : 335 - 359
  • [40] Exploring the therapeutic potential of prolinamides as multi-targeted agents for Alzheimer’s disease treatment: molecular docking and molecular dynamic simulation studies
    Samuel O. Olalekan
    Vincent A. Obakachi
    Abosede A. Badeji
    Oyesolape B. Akinsipo (Oyelaja)
    Oluwole Familoni
    Olayinka T. Asekun
    Segun D. Oladipo
    Adejoke D. Osinubi
    In Silico Pharmacology, 12 (2)